Combination therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a combination of a drug called chidamide with immunotherapy and anti-angiogenic therapy (which blocks blood supply to tumors) for advanced colorectal cancer that is MSS-type. The goal is to see how effective this combination is in real-world settings, meaning it may offer a new option for people whose cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have advanced colorectal cancer that has spread or cannot be removed, with a specific type called MSS or pMMR (confirmed by a lab test).
- You have had at least one treatment response evaluation (like a scan) after treatment.
- You have been taking chidamide for at least 3 weeks.
- You are able to care for yourself and are not bedridden (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. It may help control the cancer and improve quality of life.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.